FDA approves a new LGA-3 immune checkpoint inhibitor

May 16, 2022

FDA approves anti-LAG3 checkpoint | Nature Biotechnology (News in Brief)

"FDA approved relatlimab, the first immunotherapy that targets the LAG-3 immune checkpoint pathway, to be given in combination with the previously approved immunotherapy nivolumab, for people aged 12 and older with untreated unresectable or metastatic melanoma." by Max Maleet, Cancer Research Institute

FDA Approves New LAG-3 Checkpoint Inhibitor Immunotherapy Combination - Cancer Research Institute (CRI)